Advertisement

Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease

  • Eniko Barczi
  • Livia Starobinski
  • Abigel Kolonics-Farkas
  • Noemi Eszes
  • Aniko Bohacs
  • Martina Vasakova
  • Karel Hejduk
  • Veronika MüllerEmail author
Brief Report
  • 34 Downloads

Abstract

Introduction

Idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases with limited survival. The effect of IPF therapy in patients with severely impaired lung function is not well established. The aim of this study was to characterize IPF patients with a forced vital capacity (FVC) < 50% (group 1) and FVC 50–60% predicted (group 2) and analyze the effect and adverse events of nintedanib in Hungarian patients diagnosed between April 2015 and July 2017.

Methods

The impact of nintedanib therapy on lung function, survival, and adverse events was analyzed longitudinally.

Results

Twenty-two out of 103 patients were included in the analysis (group 1: N = 10; male/female = 6:4, age 62.6 ± 10.8 years and group 2: N = 12; male/female = 3:9, age 65.7 ± 11.6 years). Eighteen patients were treated with nintedanib (8 in group 1, 10 in group 2); treatment stabilized lung function in 42% and 50%, respectively, in the two groups. Median survival was 444 days for group 1 and 476 days for group 2. Adverse events were less common than in clinical trials; dose reduction was necessary in three cases, drug discontinuation in two cases. No differences between groups were identified regarding clinical parameters and radiological pattern; however, hypertension as comorbidity was more common in group 1 patients.

Conclusions

Nintedanib therapy was effective and well tolerated even among patients with severely impaired lung function. Longitudinal follow-up confirmed high mortality in patients with very severe and severe IPF; however, median survival was meaningful as it exceeded 1 year in both groups.

Keywords

IPF Nintedanib Pharmacotherapy Respiratory/pulmonary Safety Severe IPF Survival 

Notes

Acknowledgements

The authors would like to thank all the members of EMPIRE registry.

Funding

The EMPIRE registry is supported by a grant from Boehringer Ingelheim (since 2014). Eniko Barczi is supported by “Development of scientific workshops of medical, health sciences and pharmaceutical educations” (EFOP-3.6.3-VEKOP-16-2017-00009). Article processing charges were funded by Masaryk University. All authors had full access to all of the data in this study and took complete responsibility for the integrity of the data and accuracy of the data analysis.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures

Veronika Müller received consultation fees or travel grants from Boehringer Ingelheim and Roche. Aniko Bohacs received consultation fees or travel grants from Boehringer Ingelheim and Roche. Noemi Eszes received consultation fees or travel grants from Boehringer Ingelheim and Roche. Eniko Barczi, Livia Starobinski, Abigel Kolonics-Farkas, Martina Vasakova, and Karel Hejduk declare having nothing to disclose.

Compliance with Ethics Guidelines

The study protocol was approved by the Ethical Committee of Semmelweis University. Regional and Institutional Committee of Science and Research Ethics (TUKEB 69/2015) in accordance with the Declaration of Helsinki. Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. 1.
    Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.CrossRefGoogle Scholar
  2. 2.
    Pathogenesis of idiopathic pulmonary fibrosis [database on the Internet]. Wolters Kluwer. 2017. https://www.uptodate.com/contents/pathogenesis-of-idiopathic-pulmonary-fibrosis. Accessed 1 Jul 2017.
  3. 3.
    Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51(5):1800692.CrossRefGoogle Scholar
  4. 4.
    Taskar VS. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc. 2006;3(4):293–8.CrossRefGoogle Scholar
  5. 5.
    Raghu G. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27(1):136–42.CrossRefGoogle Scholar
  6. 6.
    Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178(7):729–37.CrossRefGoogle Scholar
  7. 7.
    Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society white paper. Lancet Respir Med. 2018;6(2):138–53.CrossRefGoogle Scholar
  8. 8.
    King TE, Bradford WZ, Castro-Bernadini S, et al. The ASCEND study: a randomized, double-blind, placebo controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF). In: A95 SKYFALL: late breaking clinical trials in idiopathic pulmonary fibrosis. American Thoracic Society; 2014. (American Thoracic Society International Conference Abstracts). https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A6602. Accessed 1 Aug 2018.
  9. 9.
    Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.CrossRefGoogle Scholar
  10. 10.
  11. 11.
  12. 12.
    Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–19.Google Scholar
  13. 13.
    Miller MR. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38.CrossRefGoogle Scholar
  14. 14.
    ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–7.Google Scholar
  15. 15.
    EuroQol Group. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy Amst Neth. 1990;16(3):199–208.CrossRefGoogle Scholar
  16. 16.
    van Reenen M, Oppe M. EQ-5D-3L user guide: basic information on how to use the EQ-5D-3L instrument. EuroQol Group. 2015. https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-3L_UserGuide_2015.pdf
  17. 17.
    Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684–91.CrossRefGoogle Scholar
  18. 18.
    Baji P, Brodszky V, Rencz F, Boncz I, Gulácsi L, Péntek M. Health status of the Hungarian population between 2000–2010. Orv Hetil. 2015;156(50):2035–44.CrossRefGoogle Scholar
  19. 19.
    Harari S, Caminati A, Poletti V, et al. A real-life multicenter national study on nintedanib in severe idiopathic pulmonary fibrosis. Respiration. 2018;95(6):433–40.CrossRefGoogle Scholar
  20. 20.
    Wuyts WA, Kolb M, Stowasser S, Stansen W, Huggins JT, Raghu G. First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of ≤ 50 % of predicted value. Lung. 2016;194(5):739–43.CrossRefGoogle Scholar
  21. 21.
    Jo HE, Glaspole I, Grainge C, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J. 2017;49(2):1601592.CrossRefGoogle Scholar
  22. 22.
    Hopkins RB, Burke N, Fell C, Dion G, Kolb M. Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur Respir J. 2016;48(1):187–95.CrossRefGoogle Scholar
  23. 23.
    European Medicines Agency. Pharmacovigilance-Medicines under additional monitoring. 2018. https://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000365.jsp&mid=WC0b01ac058067bfff. Accessed 4 Aug 2018.
  24. 24.
    Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–87.CrossRefGoogle Scholar
  25. 25.
    Noth I, Oelberg D, Kaul M, Conoscenti CS, Raghu G. Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA. Eur Respir J. 2018;52(1):1702106.CrossRefGoogle Scholar
  26. 26.
    Liang Z, Hoffman LA, Nouraie M, et al. Referral to palliative care infrequent in patients with idiopathic pulmonary fibrosis admitted to an intensive care unit. J Palliat Med. 2017;20(2):134–40.CrossRefGoogle Scholar
  27. 27.
    Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016;194(3):265–75.Google Scholar

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2019

Authors and Affiliations

  • Eniko Barczi
    • 1
  • Livia Starobinski
    • 1
  • Abigel Kolonics-Farkas
    • 1
  • Noemi Eszes
    • 1
  • Aniko Bohacs
    • 1
  • Martina Vasakova
    • 2
  • Karel Hejduk
    • 3
  • Veronika Müller
    • 1
    Email author
  1. 1.Department of PulmonologySemmelweis UniversityBudapestHungary
  2. 2.Department of Respiratory Diseases of the First Faculty of MedicineCharles University, Thomayer HospitalPragueCzech Republic
  3. 3.Masaryk UniversityBrnoCzech Republic

Personalised recommendations